Eczema Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have had atopic dermatitis (a type of chronic skin condition, also called eczema) for at least 3 years before the start of the trial
- People whose condition meets a recognised set of medical guidelines for diagnosing atopic dermatitis, known as the UK Working Party criteria (confirm with trial site)
- People whose eczema severity scores at least 16 on a standard medical measurement called the EASI score, which means the condition is moderate to severe
- People who have eczema covering at least 10% of their body surface area at the time of their first trial visit
Who may not be able to join:
- People who have medical reasons that would make it unsafe for them to take either of the two study medications — upadacitinib or dupilumab — based on the official safety guidelines for those medications (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jochen M Schmitt, Center for Evidence-based Healthcare, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden
Phone: +4935145889937
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
POEM
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.